Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Evolocumab for treating primary hyperlipidaemia and mixed dyslipidaemia [ID765]

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Company • Amgen Patient/carer groups • HEART UK Professional groups • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • UK Clinical Pharmacy Association Others • Department of Health • NHS Barking & Dagenham CCG • NHS England • NHS Walsall CCG • Welsh Government	General • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland Comparator companies • Abbott Healthcare (fenofibrate)**(Confidentiality agreement not signed, not participating)** • Accord Healthcare (fluvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Actavis (atorvastatin, bezafibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Arrow Generics (atorvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Aspire Pharma (atorvastatin, fluvastatin) • AstraZeneca (rosuvastatin) **(Confidentiality agreement not signed, not participating)** • Aurobindo Pharma (simvastatin) **(Confidentiality agreement not signed, not participating)** • Bristol Laboratories (simvastatin) **(Confidentiality agreement not signed, not participating)** • Bristol-Myers Squibb (colestyramine, pravastatin) **(Confidentiality agreement not signed, not**

Consultees	Commentators (no right to submit or appeal)
	participating) • Chanelle Medical UK (simvastatin) **(Confidentiality agreement not signed, not participating)** • Dexcel Pharma (atorvastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Discovery Pharmaceuticals (simvastatin) **(Confidentiality agreement not signed, not participating)** • Dr Reddy's Laboratories (atorvastatin) • Genus (fenofibrate) **(Confidentiality agreement not signed, not participating)** • Medreich (pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Merck Sharp & Dohme (ezetimibe, simvastatin, simvastatin with ezetimibe) • Mylan (benzafibrate, fluvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Novartis Pharmaceuticals (fluvastatin) **(Confidentiality agreement not signed, not participating)** • Pfizer (acipimox, atorvastatin, colestipol, gemfibrozil) **(Confidentiality agreement not signed, not participating)** • Ranbaxy UK (atorvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Sandoz (bezafibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Sanofi (colesevelam) • Teva UK (atorvastatin, bezafibrate, colestyramine, fenofibrate, fluvastatin, gemfibrozil, pravastatin, simvastatin) **(Confidentiality agreement not**

Consultees	**Commentators (no right to submit or appeal)**
	signed, not participating) • Wockhardt UK (atorvastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** • Zentiva (atorvastatin, ciprofibrate, fenofibrate, fluvastatin, pravastatin, simvastatin) **(Confidentiality agreement not signed, not participating)** <u>Relevant research groups</u> • None <u>Evidence Review Group</u> • School of Health and Related Research (ScHARR) • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • None <u>Associated Public Health Groups</u> • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.